Psoriasis PDA References

All decision aids are based on best available clinical evidence.

References for the psoriasis patient decision aid include:

Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo-and active comparator–controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology. 2017 Mar 1;76(3):405-17.

Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatology and Therapy. 2016 Mar 1;6(1):1-2.

Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis. June 2009. Available from: http://www.dermatology.ca/media/guidelines/

Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, Lee K, Bhutani T, Koo J. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy. 2016 Mar 1;6(1):25-37.

Global Psoriasis Atlas. Prevalence Data: Canada [Internet]. [2020]. Available from: https://globalpsoriasisatlas.org/statistics/prevalence

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine. 2016 Jul 28;375(4):345-56.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet. 2018 Aug 25;392(10148):650-61.

Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA,

Kaufman MB. Pharmaceutical Approval Update. Pharmacy and Therapeutics. 2016 Jun;41(6):355.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 2015 Aug 8;386(9993):541-51.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E. Secukinumab in plaque psoriasis—results of two phase 3 trials. New England Journal of Medicine. 2014 Jul 24;371(4):326-38.

Lebwohl M, Blauvelt A, Paul C, Sofen H, Węgłowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology. 2018 Aug 1;79(2):266-76.

Leonardi CL, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. Journal of the American Academy of Dermatology. 2008 May 31;58(5):851-64.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2008 May 31;58(5):826-50.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. Journal of the American Academy of Dermatology 2009 Apr;60:643-59.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Journal of the American Academy of Dermatology. 2009 Sep 30;61(3):451-85.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the management and treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology 2010;62:114-35.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DM, Elewski BE. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019 Feb 13;80(4):1029-72.

Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. Journal of the American Academy of Dermatology. 2008 Jan 1;58(1):106-15.

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W. S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update. Journal der Deutschen Dermatologischen Gesellschaft. 2012 Mar 1;10(s2):S1-s95.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, Jong EM. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology. 2015 Dec 1;29(12):2277-94.

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology. 2009 Oct 1;23(s2):1-70.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). British Journal of Dermatology. 2015 Dec 1;173(6):1387-99.

Product Information. Cimzia (certolizumab). UCB Inc., Smyrna, GA. Updated: 2017.

Product Information. Cosentyx (Secukinumab). Novartis Pharmaceuticals Corporation, East Hanover, NJ. Updated: 2014.

Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ. Updated: 2015.

Product Information. Enbrel (etanercept). Immunex Corporation, Thousand Oaks, CA. Updated: 2012.

Product Information. Humira (adalimumab). Abbott Laboratories, North Chicago, IL. Updated: 2011.

Product Information. Ilumya (tildrakizumab). Merck & Co. Inc., Whitehouse Station, NJ. Updated: 2018.

Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.

Product Information. Remicade (infliximab). Janssen Biotech Inc., Horsham, PA. Updated: 2013.

Product Information. Siliq (brodalumab). Valeant Pharmaceuticals, Bridgewater, NJ. Updated: 2017.

Product Information. Skyrizi (risankizumab). Abbvie Inc., North Chicago, IL. Updated: 2019.

Product Information. Stelara (ustekinumab). Janssen Biotech Inc., Horsham, PA. Updated: 2016.

Product Information. Taltz (ixekizumab). Eli Lilly and Company, Indianapolis, IN. Updated: 2016.

Product Information. Taltz (ixikizumab). Eli Lilly and Company, Indianapolis, IN. Updated: 2019.

Product Information. Tremfya (gesulkumab). Janssen Biotech Inc., Horsham, PA. Updated: 2017.

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo-and active comparator–controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology. 2017 Mar 1;76(3):418-31.

Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet. 2017 Jul 15;390(10091):276-88.

Ryoo JY, Yang HJ, Ji E, Yoo BK. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis. Annals of Pharmacotherapy. 2016 May 1;50(5):341-51.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews. 2017, Issue 12. Art. No.: CD011535.

Smith N, Weymann A, Tausk FA, Gelfand JM. Complementary and alternative medicine for psoriasis: A qualitative review of the clinical trial literature. Journal of the American Academy of Dermatology. 2009 November; 61:841-56.

Tan J, Wolfe B. A patient decision aid for psoriasis based on current clinical practice guidelines. Archives of Dermatology. 2012 Jun 1;148(6):718-23.

Youngson RM. Collins dictionary of Medicine fourth edition. 2005.